Arthritis, Rheumatoid Clinical Trial
— SPARTA-IIOfficial title:
Phase I/II Open Label Evaluation of Safety and Feasibility of 6 Months IV PRTX-100 Administrations in Previous Rheumatoid Arthritis Study Participants and Development of Immunological Samples for Assay Development From Normal Volunteers
Verified date | October 2018 |
Source | Protalex, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Part A Primary Objective To determine the safety of six months of PRTX-100 administration.
Part B Primary Objective To obtain antisera from normal volunteers that have developed
anti-PRTX-100 antibodies.
Secondary Objective(s) To assess rheumatoid arthritis activity during the period of PRTX-100
treatment To evaluate the development of anti-PRTX-100 antibodies To explore feasibility of
joint evaluations with ultrasound To explore feasibility of biomarkers as disease markers
Status | Completed |
Enrollment | 13 |
Est. completion date | November 30, 2016 |
Est. primary completion date | April 18, 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Part A Inclusion Criteria: 1. Has completed the written informed consent process 2. Received PRTX-100 or placebo in Study 104 3. Receiving methotrexate or leflunomide therapy for at least 12 weeks 4. Must be on a stable weekly dose of methotrexate (12.5 to 25 mg) or daily leflunomide (10-20 mg/day) by the same route of administration for at least 3 weeks prior to the start of study drug. 5. Agrees to notify the investigator when deviating from protocol requirements for concomitant medications 6. Agrees to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study 7. Agrees to avoid elective surgery for the full duration of the study 8. For female subjects: agrees to avoid pregnancy from 28 days prior to Study Day 0 and for the full duration of the study. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods of avoiding pregnancy include a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), or the combination of a condom or diaphragm with spermicide. Part A Exclusion Criteria: 1. Diagnosis of any other inflammatory arthritis (e.g. psoriatic arthritis, spondyloarthropathy, gout) 2. ACR Functional Classification IV 3. Systemic involvement secondary to rheumatoid arthritis (vasculitis, pulmonary fibrosis or Felty's syndrome. Secondary Sjogren's syndrome is permitted. 4. Any receipt of abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, tocilizumab or tofacitinib within 3 weeks of Study Day 0 5. Any receipt of infliximab within 6 weeks of Study Day 0 6. Any receipt of rituximab or other anti-CD20 antibodies within 12 months of study day 0 7. Any receipt of another investigational product within 4 weeks or 4 half-lives whichever is longer prior to Study Day 0 8. Hepatitis B surface antigen positive, HIV positive, hepatitis C antibody positive 9. Uncontrolled Type 2 Diabetes or Type I diabetes 10. Positive urine pregnancy test 11. Diagnosis of hepatic cirrhosis 12. Urinalysis must reflect no evidence of systemic or local disease process 13. Severe anemia, defined as < 10 g/dL or hematocrit < 30% 14. Evidence of significant active infection 15. Shared a residence within the last year with an individual on anti-tuberculosis treatment or with culture or smear positive tuberculosis 16. Previous medical history that may compromise the safety of the subject in the study, including but not limited to: severe impairment of pulmonary function or other pulmonary disease; chronic illness with signs of cardiac or renal failure; suspected progressive neurological disease or poorly controlled epilepsy 17. Evidence of a new acute illness that may compromise the safety of the subject in the study 18. History or evidence on physical examination of any systemic disease or any acute or chronic illness that, in the opinion of the investigator, may interfere with the evaluation of the safety of the study drug 19. History or evidence (including chest X-ray) of active tuberculosis 20. Any current medical, psychiatric, occupational, or substance abuse problems that, in the opinion of the investigator, will make it unlikely that the subject will comply with the protocol. Part B Inclusion Criteria 1. Has completed the written informed consent process 2. Is in a state of good health 3. Agrees to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study 4. Agrees to avoid elective surgery for the full duration of the study 5. For female subjects: agrees to avoid pregnancy from 28 days prior to Study Day 0 and for the full duration of the study. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods of avoiding pregnancy include a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), or the combination of a condom or diaphragm with spermicide. Part B Exclusion Criteria 1. Diagnosis of cancer or autoimmune disease. 2. Any receipt of another investigational product within 4 weeks or 4 half-lives whichever is longer prior to Study Day 0 3. Hepatitis B surface antigen positive, HIV positive, hepatitis C antibody positive 4. Uncontrolled Type 2 Diabetes or Type I diabetes 5. Diagnosis of hepatic cirrhosis 6. Positive urine pregnancy test 7. Urinalysis must reflect no evidence of systemic or local disease process 8. Severe anemia, defined as < 10 g/dL or hematocrit < 30% 9. Previous medical history that may compromise the safety of the subject in the study, including but not limited to: severe impairment of pulmonary function or other pulmonary disease; chronic illness with signs of cardiac or renal failure; suspected progressive neurological disease or poorly controlled epilepsy 10. Evidence of a new acute illness that may compromise the safety of the subject in the study 11. History or evidence on physical examination of any systemic disease or any acute or chronic illness that, in the opinion of the investigator, may interfere with the evaluation of the safety of the study drug 12. Any current medical, psychiatric, occupational, or substance abuse problems that, in the opinion of the investigator, will make it unlikely that the subject will comply with the protocol. |
Country | Name | City | State |
---|---|---|---|
United States | Protalex Investigational Site | Coeur d'Alene | Idaho |
Lead Sponsor | Collaborator |
---|---|
Protalex, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Sera Collection | To obtain antisera from normal volunteers that have developed anti-PRTX-100 antibodies. | 77 Days | |
Primary | Safety (Analysis of Adverse Events) | Number, severity, and attribution of relatedness of Adverse Events will be analyzed. | 6 months | |
Secondary | ACR-28 joint count | ACR 28-joint counts (number of tender and swollen joints) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity. | 6 months | |
Secondary | Patient's global assessment of disease activity | Patient's global assessment of disease activity (0-10) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity. | 6 months | |
Secondary | Patient's assessment of pain VAS | Patient's assessment of pain VAS (0-10) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity. | 6 months | |
Secondary | Physician's global assessment of disease activity | Physician's global assessment of disease activity (0-10) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity. | 6 months | |
Secondary | MDHAQ - Physical Function | MDHAQ Physical Function (0-10) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity. | 6 months | |
Secondary | MDHAQ - Joint Pain | MDHAQ Joint Pain (0-48) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity. | 6 months | |
Secondary | MDHAQ - Fatigue | MDHAQ Fatigue (0-10) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity. | 6 months | |
Secondary | RAPID 3 | RAPID 3 (0-30) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity. | 6 months | |
Secondary | CDAI | Clinical Disease Activity Index (0-76) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity. | 6 months | |
Secondary | DAS28-CRP | DAS28-CRP (0-10) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity. | 6 months | |
Secondary | hsCRP | C-Reactive Protein (hsCRP) lab values (mg/dL) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity. | 6 months | |
Secondary | ESR | Erythrocyte Sedimentation Rate (mm/hr) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity. | 6 months | |
Secondary | Biomarker Correlation | Vectra-DA scores (1-100) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity. | 6 months | |
Secondary | Disease activity | ACR 28-joint counts (tender and swollen), patient's global assessment of disease activity, patient's assessment of pain VAS, physician's global assessment of disease activity, MDHAQ (overall, physical function, joint pain, and fatigue), RAPID 3, CDAI, DAS28-CRP, CRP, ESR, Vectra-DA, and UPD joint counts, will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity. | 6 months | |
Secondary | Ultrasound Power Doppler Joint Count | UPD joint counts (0-36) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity. | 6 months | |
Secondary | Immunogenicity | The occurrence of anti-PRTX-100 antibodies (positive/negative) will be summarized descriptively for the observed values and change from baseline results. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01682512 -
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT00539760 -
A Phase I Rheumatoid Arthritis Study in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03312465 -
Anatomical Shoulder Domelock System Study
|
||
Completed |
NCT01208181 -
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
|
Phase 3 | |
Completed |
NCT03254810 -
Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT01711814 -
A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
|
Phase 2 | |
Completed |
NCT03315494 -
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers
|
Phase 1 | |
Withdrawn |
NCT03241446 -
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
|
Phase 1 | |
Completed |
NCT02553018 -
Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe
|
Phase 3 | |
Completed |
NCT02748785 -
MTX Discontinuation and Vaccine Response
|
Phase 4 | |
Active, not recruiting |
NCT02260778 -
Treat-to-target in RA: Collaboration To Improve adOption and adhereNce
|
N/A | |
Completed |
NCT02569736 -
Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
|
||
Completed |
NCT01750931 -
This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
|
Phase 2 | |
Not yet recruiting |
NCT01154647 -
Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes
|
N/A | |
Withdrawn |
NCT01204138 -
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA
|
Phase 2 | |
Completed |
NCT00975130 -
Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
|
Phase 3 | |
Completed |
NCT00973479 -
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
|
Phase 3 | |
Completed |
NCT00913458 -
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
|
Phase 4 | |
Completed |
NCT00550446 -
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
|
Phase 2 | |
Completed |
NCT00660647 -
Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)
|
Phase 3 |